Fintel on MSN14h
Oppenheimer Upgrades Nektar Therapeutics (NKTR)Fintel reports that on March 14, 2025, Oppenheimer upgraded their outlook for Nektar Therapeutics (NasdaqCM:NKTR) from ...
Nektar Therapeutics (NASDAQ:NKTR – Get Free Report)‘s stock had its “market perform” rating reissued by analysts at William ...
Treatment-experienced patients with moderate to severe atopic dermatitis attained higher efficacy rates on rocatinlimab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback